Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
about
ESUR prostate MR guidelines 2012Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment.Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up studyOutcomes of active surveillance for men with intermediate-risk prostate cancer.Active surveillance in prostate cancer: a concept analysis.Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.Watchful waiting for prostate cancer: a review article.Current role of prostate-specific antigen kinetics in managing patients with prostate cancer.Active surveillance vs radical prostatectomy.The '2-week wait' rule for referrals for suspected urological cancers--urgent need for refinement of criteria.The current status of active surveillance for prostate cancer.Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocitySignificance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.MRI-compatible transurethral ultrasound system for the treatment of localized prostate cancer using rotational control.
P2860
Q24620926-29B373A4-F4A0-443D-9FE6-10896976F6D1Q30364894-D4B781C3-02D1-4CB6-80B2-53BC2FABBFC3Q33965083-D2C8AA93-EE15-4C24-911E-49784B6F7E99Q34679207-B7DE3CF8-99E3-49E1-990A-0A0954DFA560Q35898357-1D40FD55-5C28-41D5-A3CB-0231334305ACQ35924445-1A35DB55-F798-4ED5-A04A-8D3322E77BCFQ36364398-AF1A4ABA-9D78-4CE1-BF46-F2137D4E4113Q36392168-EEDAC5B8-6E1A-4A4E-82CC-87ECBC378B45Q36861748-CA62852D-2CE3-4141-AA4B-656E4CB532F4Q37108357-32338F7A-58AE-4043-A2B0-B1530BC034C6Q38018211-C45528C6-83AA-4EBA-BFCF-93395768F5CEQ39583146-A91E3116-7738-4465-9715-789D06B1059EQ39811058-F127E977-2805-4ECB-A6B8-EDA38FA73674Q39812931-5C6BAD6F-82CD-4B86-B7BB-4838E51C7AF6Q42424388-93BEA53C-00F6-4465-8BA6-2EB76E228207Q43515207-54AA340C-0966-4F24-A5E9-DB9965EFB459Q45359397-4456FD18-ABDD-4EF3-8302-0864BCC20C82Q46564602-993CFC41-1268-4A70-888C-CA10BA1A3012Q47695858-466F811A-AAD6-407E-9506-35B1F2F56AAE
P2860
Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Active surveillance with selec ...... for good risk prostate cancer.
@ast
Active surveillance with selec ...... for good risk prostate cancer.
@en
type
label
Active surveillance with selec ...... for good risk prostate cancer.
@ast
Active surveillance with selec ...... for good risk prostate cancer.
@en
prefLabel
Active surveillance with selec ...... for good risk prostate cancer.
@ast
Active surveillance with selec ...... for good risk prostate cancer.
@en
P1433
P1476
Active surveillance with selec ...... for good risk prostate cancer.
@en
P356
10.1016/J.EURURO.2004.09.010
P407
P577
2005-01-01T00:00:00Z